Breast Surgery Articles & Analysis
41 news found
Dirbas, MD, Associate Professor of Surgery, Division of Surgical Oncology, Stanford School of Medicine and Mark D. ...
After 3 years of work, we announce the start of our clinical trials and the inclusion of a first patient eligible for breast reconstruction with #MATTISSE for her breast cancer. This is a world first for this type of technology, #madeinfrance totally resorbable, 3D printed, allowing a natural breast reconstruction, with a simple and unique ...
Highlights Discussions held with US and EU Regulators and Clinical Key Opinion Leaders Proposing two Phase 3 studies in two major surgery types to aim to provide a broad surgery label for XF-73 Nasal Phase 3 programme will deliver an approvable data package for both US and EU authorities. ...
The first application of its technology is for breast reconstruction after cancer. Currently, one out of woman gets sooner or later breast cancer. ...
After the entry into clinical phase announced in early July 2022, LATTICE MEDICAL, announces the success of the first breast reconstruction operation with the MATTISSE implant. The operation took place on July 12 at the Institute of Clinical Oncology, Tbilisi, Georgia. It was conducted by Pr Gia Nemsdaze and his team, and in the presence of the co-founders of Lattice Medical, Pr. Pierre ...
Pavilion Surgery Center, an affiliate of St. Joseph Hospital, along with Perimeter Medical Imaging AI, Inc. ...
QView Medical is pleased to announce FDA approval for QVCAD to be used with the GE Invenia™ ABUS in breast screening for asymptomatic dense breasted women whose mammogram was negative. QVCAD is the next generation CAD system for automated breast ultrasound ("ABUS") based on deep learning algorithms. The QVCAD innovative C-Thru technology combined with ABUS has demonstrated a 33% improved ...
National Institutes of Health (NIH)’s National Cancer Institute (NCI) to advance development of its proprietary device for Fluorescence-Guided Surgery (FGS). OnLume has developed novel FGS imaging technology to illuminate critical anatomy in real-time during surgery to optimize precision, which can lead to improved patient outcomes, reduced morbidity and ...
The results of the study demonstrated that after breast conserving surgery (BCS) patients in the DCISionRT elevated risk group had a significant risk reduction from endocrine therapy (ET), while those patients in the DS low risk group did not have a significant risk reduction from ET. ...
The results evaluating the association of DCISionRT, a predictive DCIS Biosignature to assess the impact of Endocrine Therapy (ET) on 10-year ipsilateral breast recurrence (IBR) risk after breast conserving surgery alone or with radiation therapy (RT), will be presented on June 7, 2022 at McCormick Place, Chicago, IL. ...
Scientific Presentation: Cryoablation of Low-Risk Breast Cancer An Update of the ICE3 Trial Dr. Kenneth R. Tomkovich, Co-Primary Investigator of the ICE3 trial, presented promising interim data on cryoablation of small, low-risk breast cancers on April 26. ...
Patients with DCIS have cancerous cells lining the milk ducts of the breast, but they have not spread into surrounding breast tissue. In the US, over 60,000 women are newly diagnosed with DCIS each year. ...
” The Versius® Surgical Robotic System Versius® resets expectations of robotic surgery. Versius fits into virtually any operating room set-up and integrates seamlessly into existing workflows, increasing the likelihood of robotic minimal access surgery (MAS). ...
Patients with DCIS have cancerous cells lining the milk ducts of the breast, but they have not spread into surrounding breast tissue. In the US, over 60,000 women are newly diagnosed with DCIS each year. ...
The study included 493 patients from three cohorts who were treated with breast conserving surgery (BCS) or BCS + radiation therapy (RT). DCISionRT and its RRt classified patients into Low, Elevated and Residual Risk groups with the Residual Risk group having the highest 10-year ipsilateral breast recurrence (IBR) risk without RT and ...
Approximately 300 patients undergoing breast conservation surgery across eight U.S. clinical sites are expected to participate in the pivotal trial, with study completion anticipated by the end of 2022. ...
(TSX-V:PINK)(OTC:PYNKF) (FSE:4PC) (“Perimeter” or the “Company”), a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs, announced the initiation of a multi-center, randomized, two-arm pivotal clinical trial to evaluate its Perimeter B-Series OCT ...
“Additionally, we are encouraged by results from a study validating our new 16-gene genomic radiation therapy signature in development, showing promise in identifying women with early-stage breast cancer who may be able to forgo irradiation following breast conserving ...
” The study assessed 10-yr outcomes in 504 women treated with breast conserving surgery (BCS) and randomized into RT or no RT arms. ...
Alastair Thompson, Principal Investigator and Professor, Section Chief of Breast Surgery and Olga Keith Wiess Chair of Surgery at Baylor College of Medicine and the Dan L Duncan Comprehensive Cancer Center said, “Currently, approximately one in four women who undergo breast conservation surgery require ...